MoH, Malaysia, awards three-year contract to Biocon Biologics’s Insugen
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
The Ministry of Health (MoH), Malaysia, has awarded a three-year contract to Biocon Biologics’s human insulin brand Insugen valued at $90 million (MYR 375 million), a statement from Biocon notified.
It said that Biocon Sdn Bhd, a subsidiary of Biocon Biologics in Malaysia, will manufacture and supply its range of insulins to its partner Duopharma Marketing Sdn Bhd (DMktg), a subsidiary of Duopharma Biotech, a pharma and biotech company in Malaysia.
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics, the statement added.
Further, according to the statement, the rh-Insulin formulations, Insugen-R, Insugen-N and Insugen-30/70, are manufactured at Biocon Sdn Bhd’s Johor facility, and have been approved by the National Pharma Regulatory Authority (NPRA), Malaysia.
Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins. The state-of-the-art insulins facility in Johor is the first and only biopharma sterile injectables facility in Malaysia to receive the US FDA and EMA approval, the statement concluded.